Cell Therapy

Neowise and BeOne Medicines sign agreement for cell therapy development

Neowise Biotechnology has entered into a licensing agreement with BeOne Medicines, granting the latter rights to antigen-specific TCR molecule for the development of off-the-shelf cell therapies.

Porton Advanced and Eureka to expedite T-cell therapy development

Contract development and manufacturing organisation (CDMO) Porton Advanced has announced a partnership with Eureka Therapeutics to expedite the worldwide clinical development of T-cell therapies.

FDA approves StemCyte’s cord blood stem cell therapy BLA

The US Food and Drug Administration (FDA) has granted approval for StemCyte's biologics license application (BLA) for REGENECYTE, a hematopoietic progenitor cell (HPC), Cord Blood product.

Lyell signs agreement to acquire ImmPACT Bio

Lyell Immunopharma has entered into a definitive agreement for the acquisition of ImmPACT Bio USA, a move that is expected to prioritise its pipeline to focus on chimeric antigen receptor (CAR) T-cell therapies.

BMS to boost CAR T cell therapy production with Cellares deal

Bristol Myers Squibb (BMS) has entered into worldwide capacity reservation and supply agreement with Integrated Development and Manufacturing Organisation (IDMO) Cellares to bolster the manufacturing of chimeric antigen receptor (CAR) T cell therapies.

AGC concludes cell and gene therapy site expansion in Milan, Italy

AGC Biologics has concluded expansion of its manufacturing area at its Cell & Gene Center of Excellence production site in Milan, Italy.

eXmoor pharma raises $35m to boost cell and gene therapy production

eXmoor pharma has received an investment of around $35m in its Series A round to support the expansion of its cell and gene therapy production capability.

CAMP4 Therapeutics closes $100m round to advance lead regRNA programmes

Biotechnology company CAMP4 Therapeutics has closed a $100m Series B round to progress its lead regRNA programmes and speed up the expansion of its regRNA Actuating Platform.

Castle Creek Biosciences raises $112.8m to progress gene therapies

Castle Creek Biosciences, a US-based late-stage cell and gene therapy company, has raised $112.8m to progress new gene therapies and expand pipeline.